Cystic fibrosis, a common hereditary disease affecting 1 in 2,000 live births among whites and 1 in 17,000 among blacks (6), is characterized by recurrent episodes of bronchopneumonia frequently due to Pseudomonas aeruginosa (10) . Cefsulodin sodium, a new semisynthetic third generation cephalosporin, has a high degree of activity against P. aeruginosa but very limited activity against other gramnegative pathogens (13) . It is reported to be four-to eightfold more active than carbenicillin against P. aeruginosa (11), presumably owing to its increased affinity for penicillinbinding protein lb and relative stability to the cephalosporinases of P. aeruginosa (12) .
As with other cephalosporins, the excretion of cefsulodin is primarily renal, with 40 to 70% of the administered dose recovered from the urine within 24 h (14) . It has a half-life of 1.6 h after intravenous administration in patients with normal kidney function (8) and 6 to 13 h in patients with moderate and severe impairment of renal function (7) . The purpose of this report is to document the safety and efficacy of cefsulodin sodium in the therapy of Peak plasma levels ranged from 31 to 139 vig/ml with mean levels of 46, 71, and 90 pLg/ml, respectively, after 500-, 1,000-, and 1,500-mg doses (Fig. 1) . Sputum levels ranged from 2 to 5 pg/ml in eight patients and 19 samples and were less than 2 iag/ml in seven patients and 18 samples. Two patients (no. 4 and 6) had levels <2 p.g/ml in all their samples (Fig. 2) . MICs ranged from 0.2 to 128 ,ug/ml (geometric mean, 7.5 pLg/ml). Of 15 strains, 3 (20%) that required for inhibition an MIC of <16 p.g/ml were resistant (s15 mrm disk zone diameter) by Kirby-Bauer disk diffusion methods with a 30-pLg disk, whereas 9 of 10 strains (90%) that required for inhibition an MIC of .32 pLg/ml were also resistant by the disk diffusion method, for an overall correlation of 84% between MIC and disk diffusion tests.
After therapy, 13 isolates from six patients required for inhibition an MIC of .32 ,ug/ml. Three patients had isolates which appeared to have developed resistance only after therapy. Patient 3 had P. aeruginosa type 5, patient 6 had P. aeruginosa type 6, and patient 8 had P. aeruginosa type 5. In all 10 cases, colonization of lower respiratory secretions persisted after therapy, a characteristic feature in patients with cystic fibrosis. 
DISCUSSION
Cefsulodin sodium has been generally well tolerated, and only occasionally have side effects such as nausea, dizziness, allergic skin reactions, and transient elevations of blood urea nitrogen, creatinine, and transaminases been reported. In the 10 patients we studied with cystic fibrosis, no clinical or chemical side effects were noted. The putative advantage in using cefsulodin sodium as a therapeutic agent in human P. aeruginosa infections is that current antibiotic regimens (an aminoglycoside plus an antipseudomonal penicillin) present the potential for relatively increased toxicity. Such toxicity is thought to be related to the narrow gap between therapeutic and toxic levels of aminoglycosides. In addition, there is the problem of the increased metabolism of aminoglycosides in cystic fibrosis patients, which requires a larger dose of the drug to achieve the therapeutic levels (9) . On the other hand, it has been suggested that P. aeruginosa is able to develop a beta-lactamase membrane "barrier" that appears to be responsible for the resistance to beta-lactam antibiotics (15) . This 
